Commented Articles

PanNASH covers commented articles ans publications to acquire sufficient information, understanding, and skills to cope with NASH/NAFLD healthcare demands.

From NAFLD to NASH: Determining Disease Progression and Regression Rates

Authors: Noureddin and Wong
Published in Clinical Gastroenterology and Hepatology (May 2023)
The spectrum of non-alcoholic fatty liver disease (NAFLD) is divisible into three stages: 1) NAFL, 2) non-alcoholic steatohepatitis (NASH), NAFLD’s progressive and inflammatory subtype, and 3) NAFLD or NASH with fibrosis, whose stages range from F0-4.
Read MoreFrom NAFLD to NASH: Determining Disease Progression and Regression Rates

The Power of PPARs in NASH-associated Microvascular Dysfunction

Authors: Guixé-Muntet S, Biquard L, Szabo G et al.
Published in Alimentary Pharmacology and Therapeutics (July 2022)
Hepatic microvascular dysfunction is central to the development and progression of nonalcoholic steatohepatitis (NASH), the inflammatory subtype of nonalcoholic fatty liver disease (NAFLD).
Read MoreThe Power of PPARs in NASH-associated Microvascular Dysfunction

Phospholipid Depletion and NAFLD Pathophysiology: Findings from Lipidomics

Authors: Mocciaro G, Allison M, Jenkins B et al.
Published in Molecular Metabolism (April 2023)
Along with its association with metabolic syndrome, NAFLD is closely linked with mixed dyslipidaemia (reduced high-density lipoprotein cholesterol (HDL-C) and increased very low-density lipoprotein triglycerides (VLDL-TG)).
Read MorePhospholipid Depletion and NAFLD Pathophysiology: Findings from Lipidomics

Noninvasive Tests for NAFLD: Where Are We Now?

Authors: Alnimer L and Noureddin M
Published in Clinical and Molecular Hepatology (April 2023)
Up to 30% of patients with non-alcoholic fatty liver disease (NAFLD) progress to non-alcoholic steatohepatitis (NASH), significantly increasing their risk of fibrosis and associated adverse outcomes. As such, ensuring the early identification of NAFLD and NASH in at-risk patients is a clinical priority.
Read MoreNoninvasive Tests for NAFLD: Where Are We Now?

Cardiovascular Disease in MAFLD Versus NAFLD: A Review

Authors: Kang MK, Lee YR, Jang SY et al
Published in Hepatol Int (April 2023)
Changing the terminology from NAFLD, non-alcoholic fatty liver disease, to MAFLD, metabolic dysfunction-associated fatty liver disease, has been an ongoing debate. MAFLD is based upon an individual having hepatic steatosis, as well as either type 2 diabetes mellitus, obesity (or being overweight) or if at a normal weight, two or more metabolic risk abnormalities.
Read MoreCardiovascular Disease in MAFLD Versus NAFLD: A Review

NASH and Its Clinical Trials: Exciting Recent Developments

Authors: Harrison SA, Loomba R, Dubourg J et al.
Published in Clinical Gastroenterology and Hepatology (April 2023)
Patients with non-alcoholic fatty liver disease (NAFLD) are at risk of progressing to inflammatory non-alcoholic steatohepatitis (NASH), a NAFLD subtype associated with fibrosis, cirrhosis, and hepatocellular carcinoma.
Read MoreNASH and Its Clinical Trials: Exciting Recent Developments

NASHmap: A New Non-invasive Tool for NASH Identification?

Authors: Schattenberg JM, Balp MM, Reinhart B et al.
Published in Scientific Reports (April 2023)
NASHmap, a non-invasive machine learning model, is revolutionizing NASH identification. Utilizing 14 clinical variables, it offers a promising alternative to invasive liver biopsies. With an 81% positive predictive value, NASHmap can potentially improve clinical practice and specialist referrals for high-risk patients.
Read MoreNASHmap: A New Non-invasive Tool for NASH Identification?

Proteo-Transcriptomics for at-Risk NASH: The Future of Non-Invasive Risk Assessments?

Authors: Ajmera V
Published in Nature Metabolism (April 2023)
Proteo-transcriptomic analyses offer a promising approach for precise NASH risk assessment. A predictive model based on protein levels and clinical variables demonstrates 79% accuracy. This innovative method holds potential for developing blood-based diagnostic tools. Further testing in diverse populations is necessary to validate its efficacy.
Read MoreProteo-Transcriptomics for at-Risk NASH: The Future of Non-Invasive Risk Assessments?

The “Perfect” NASH Biomarker: An Unrealistic Pursuit?

Authors: Sebastiani G
Published in Lancet Gastroenterol Hepatol 2023
Seeking the perfect NASH biomarker may be unrealistic; versatility is key. A diverse biomarker pool adapts to varied clinical contexts and settings. FIB-4, a cost-effective marker, can be supplemented by complex multimarkers for NASH therapeutic trials. Embracing diagnostic imperfections is crucial for flexible biomarker algorithms.
Read MoreThe “Perfect” NASH Biomarker: An Unrealistic Pursuit?

Cardiovascular Risk in Patients with NAFLD and Inflammatory Bowel Diseases

Authors: Kablawi D, Aljohani F, Palumbo CS et al.
Published in Crohns Colitis 360 2023
NAFLD's prevalence in IBD patients raises concerns for cardiovascular risk. The study found doubled atherosclerotic cardiovascular disease risk in IBD patients with NAFLD. Transient elastography may predict cardiovascular risk in IBD patients. Targeted risk assessments are crucial for IBD patients with NAFLD.
Read MoreCardiovascular Risk in Patients with NAFLD and Inflammatory Bowel Diseases

Costs of Care for Non-Alcoholic Steatohepatitis in the United States: A Review

Authors: Tapper EB, Bonafede M, Fishman J, et al.
Published in J Med Econ 2023
The rising healthcare costs of NASH highlight the need for early intervention. Higher FIB-4 scores correlate with increased healthcare expenses. Early-stage intervention can reduce the burden on patients and the healthcare system.
Read MoreCosts of Care for Non-Alcoholic Steatohepatitis in the United States: A Review

Non-Invasive Tests and Their Cut-Offs for Assessing Fibrosis: A Review

Authors: Lazarus JV, Castera L, Mark HE, et al
Published in JHEP Rep 2022
Heterogeneity in cut-off points for non-invasive fibrosis tests impacts NAFLD risk stratification. Standardized guidelines could improve consistency and accuracy in identifying patients requiring specialist care.
Read MoreNon-Invasive Tests and Their Cut-Offs for Assessing Fibrosis: A Review

SUBSCRIBE & FOLLOW US

SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES